Blog
RSS FeedPosted by Michael Wonder on 09 Jan 2019
Stivarga final NICE recommendation for hepatocellular carcinoma
9 January 2019 - Bayer’s Stivarga has received a final green light from NICE for use by the NHS to ...
Posted by Michael Wonder on 21 Dec 2018
NICE recommends Lenvima for advanced liver cancer
21 December 2018 - NICE has recommended Eisai and MSD’s Lenvima (lenvatinib), a potentially life-extending treatment for advanced hepatocellular carcinoma ...
Posted by Michael Wonder on 19 Dec 2018
NICE authorises MSD's Keytruda for stage III melanoma
19 December 2018 - MSD’s Keytruda has been given a green light for use within the EU as an adjuvant ...
Posted by Michael Wonder on 10 Dec 2018
NICE turns down Opdivo/Yervoy combo for kidney cancer
10 December 2018 - NICE has published draft guidelines rejecting NHS funds for Opdivo/Yervoy for untreated metastatic renal cell carcinoma. ...
Posted by Michael Wonder on 07 Dec 2018
NICE OKs NHS funding for Gilead’s CAR T-cell therapy
7 December 2018 - Gilead’s CAR T-cell therapy Yescarta will be available on the NHS to some adults with lymphoma. ...
Posted by Michael Wonder on 05 Dec 2018
NICE terminates two appraisals
5 December 2018 - NICE is unable to make a recommendation about the use of two medicines in the NHS because ...
Posted by Michael Wonder on 04 Dec 2018
Flexibility on cancer drugs approval will foster innovation
4 December 2018 - Between 2000 and 2016, no new drugs were approved for cancers of the brain, and there were ...
Posted by Michael Wonder on 04 Dec 2018
New cancer drugs taking longer to reach NHS patients
4 December 2018 - NHS patients are waiting longer for new cancer drugs because of delays in taking them through ...
Posted by Michael Wonder on 30 Nov 2018
NICE U turn on Opdivo for skin cancer recurrence
30 November 2018 - NHS use of Bristol-Myers Squibb’s Opdivo to cut the risk of early stage skin cancer recurrence ...
Posted by Michael Wonder on 29 Nov 2018
Life extending treatment for patients with advanced liver cancer recommended by NICE
29 November 2018 - Approving regorafenib is a "welcome step forward" for those people who are eligible. ...
Posted by Michael Wonder on 22 Nov 2018
New life-extending lung cancer treatment approved by NICE
22 November 2018 - NICE today recommends in draft guidance that immunotherapy drug pembrolizumab (also known as Keytruda), used with ...
Posted by Michael Wonder on 19 Nov 2018
Innovative skin cancer drug available on Cancer Drugs Fund
19 November 2018 - Patients with a type of advanced skin cancer have a new treatment option as pembrolizumab, also known ...
Posted by Michael Wonder on 16 Nov 2018
NICE recommends cutting-edge therapy for young people with blood cancer
16 November 2016 - NICE has recommended a pioneering cancer treatment, CART-cell therapy, for people under the age of 25 with ...
Posted by Michael Wonder on 10 Nov 2018
NICE says no to expanding use of AstraZeneca's’ Lynparza
9 November 2018 - NICE has ruled against expanding use of AstraZeneca’s Lynparza to a wider patient population with ovarian ...
Posted by Michael Wonder on 09 Nov 2018
Lenvima backed for NHS use to treat liver cancer
9 November 2018 - NICE has issued draft guidelines backing use of Eisai/MSD’s Lenvima on the NHS in England and ...